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1 INTRODUCTION 
Clinical trials have demonstrated that selected secondary prevention medications for patients 
after acute myocardial infarction (AMI)—angiotensin-converting enzyme inhibitors 
(ACEIs)/angiotensin receptor blockers (ARBs), β-blockers, antiplatelet agents, and lipid-
lowering drugs (statins)—reduce cardiovascular mortality.1 Yet, a gap still persists between 
the benefits demonstrated in clinical trials and the effectiveness of these medications in 
clinical practice.2,3 There are two potential explanations for this discrepancy: first, these 
medications are generally underprescribed in the secondary prevention of patients;4-7 second, 
older people are underrepresented or even absent from drug trials.1,8 Elderly patients are the 
most vulnerable subgroup in the population, as they have higher cardiovascular risk, more 
comorbidities, poorer tolerability and compliance to medications,9 and higher susceptibility 
to drug interactions. 
Findings from observational studies indicate that secondary prevention medications after 
AMI are more effective and have synergistic benefits, when prescribed additively.10-13 
However, it is reasonable to assume that variations in compliance and tolerability profiles 
across younger and older age groups might alter the strength of association between 
adherence and survival. To the best of our knowledge, no population outcome study has 
attempted to determine whether polytherapy after AMI is effective on long-term mortality in 
very old patients. 
Accordingly, the objective of this study was to examine the relationship between adherence 
to evidence-based drugs and mortality following AMI in a cohort from Emilia-Romagna 
region (Northern Italy), focusing on the effect of single therapy and polytherapy in very old 
patients (≥80 years) compared with elderly and adult patients (<80 years). The findings of 
this study may have practical implications for designing interventions to improve secondary 
prevention of older patients after AMI. 
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2 MATERIALS AND METHODS 
The study was carried out in conformity with the regulations on data management of the 
Regional Health Authority of Emilia-Romagna, and with the Italian Code of conduct and 
professional practice applying to processing of personal data for statistical and scientific 
purposes (Art. 20–21, DL 196/2003) (http://www.garanteprivacy.it/web/guest/h
ome/docweb/-/docweb-display/docweb/1115480, published in the Official Journal no. 190 of 
August 14, 2004) which explicitly exempts the need of ethical approval for encrypted data 
(Preamble #8). Data were encrypted prior to the analysis at the Regional Statistical Office, 
where each patient was assigned a unique identifier. This identifier does not allow to trace 
the patient’s identity and other sensitive data. As encrypted administrative data are used 
routinely for healthcare management, no specific written informed consent was needed to 
use patient’s information. 
2.1 Setting and study population 
The study population comprised all residents of the Local Health Authoritya of Bologna in 
Northern Italy (population size 866 000 in 2012) who were hospitalized for AMI between 
January 1, 2008 and June 30, 2011. Discharge diagnosis retrieved from hospital discharge 
records (HDRs)b was used to identify eligible patients; specifically, the diagnosis of AMI 
was based on the presence of one out of the 2 following criteria: a primary diagnosis of AMI 
(ICD-9-CM codes 410.x1) or a primary diagnosis of an AMI-related condition along with a 
                                                 
a Local Health Authorities are vertically integrated organizations funded by the Italian regions through 
a capitated budget. They are responsible for a wide range of hospitals and community services in 
geographical areas with populations ranging 60 000 to 1000 000 inhabitants. 
b Information contained in HDRs is transmitted by all public and private hospitals to their own region, 
and every 6 months from the region to the Ministry of Health. Since 1995, all HDRs have been 
entered in a Hospital Information System database. The database includes demographic 
characteristics, admission and discharge dates, admission referral source, discharge status, principal 
diagnosis, up to 5 secondary diagnoses, and up to 6 interventions. The HDR-DRG (Diagnosis Related 
Group) system is systematically used to allocate funds to hospitals and to monitor quality of care and 
outcomes. 
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secondary diagnosis of AMI (Table S1 in the Appendix). Fifth-digit 1 diagnoses were 
considered in order to include in the analysis only initial episodes of care of AMI. 
Subsequent hospitalizations for any reason after the index discharge were investigated, and 
repeated admissions within 2 days of discharge were regarded as one single “episode”. The 
reference date for the beginning of the follow-up period was thus the day of hospital 
discharge of the index episode, so as to investigate home care and outpatient follow-ups. The 
end of the observation period was considered to be either death by natural causes (ICD-9-
CM codes 001–799), identified through the Regional Mortality System Database,c or end of 
the study period (December 31, 2012), whichever occurred first. In summary, the potential 
follow-up period varied between 1.5 and 5 years. 
2.1.1 Exclusion criteria 
Patients were excluded from the analysis if one of the following criteria was met: 
1) Length of stay for episode of care >35 days (95th percentile); that is, very complex or 
instable cases; 
2) Age <37 years (lower adjacent value of age), as drug prescription in very young patients 
might differ from standard therapy; 
3) Individual follow-up <30 days, to give all patients the chance to achieve clinical stability 
and to guarantee a minimum observation period of one month. 
4) Patients who spent more than 50% of their individual follow-up in the hospital, because 
drugs dispensed by the facility during inpatient treatment cannot be retrieved from the 
Outpatient Pharmaceutical Database, possibly leading to immeasurable time bias.14 
                                                 
c The Mortality Information System database includes patients’ demographic characteristics as well as 
date, place and cause of death (classified in the ICD-9-CM). 
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2.2 Selection of cases and controls 
Patients who experienced the study outcome (i.e., death by natural causes) during follow-up 
were defined as cases. Up to 8 controls were randomly selected and matched to each case 
with respect to age (5-year groups), sex, and duration of follow-up.d Thus, all controls had an 
equal duration of follow-up at the time of death. We chose this approach to ensure an equal 
time window for measuring drug exposure of cases and controls. 
2.3 Drug exposure 
Data on drug utilization were retrieved from the Regional Health Authority Outpatient 
Pharmaceutical Database, which contains information on patients (identification number, 
gender and age), prescriptions (substance name, Anatomical Therapeutic Chemical [ATC] 
Classification System code—version 2013, trade name, date of prescription filling, and 
number of packages) and prescribers. This register is limited to drugs prescribed out of the 
hospital and reimbursed by the healthcare system. 
Data on filled prescriptions during the follow-up were linked with HDRs through the 
patient’s identification code. Drugs were classified into 4 evidence-based ATC groups 
recommended for secondary prevention after AMI: 
1) ACEIs/ARBs (ATC codes C09); 
2) β-blockers (ATC codes C07); 
3) Antiplatelet drugs (ATC codes B01AC); 
4) Statins (ATC codes C10AA, C10BA, C10BX). 
All these medications are included in the Outpatient Pharmaceutical Database, and equally 
available to all residents in accordance with the universal healthcare coverage provided to 
                                                 
d This technique is called “incidence density sampling”. All subjects are eligible for selection as a 
control (including subjects who later become cases), and can also be used as controls on multiple 
occasions. 
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Italian residents. See Table S2 in the Appendix for essential information about therapeutic 
indications, side effects and main warnings of each of the 4 medication groups. 
Drugs belonging to the same ATC group were cumulated throughout the individual follow-
up, and adherence to each group was calculated using the proportion of days covered (PDC) 
on the basis of the Defined Daily Doses (DDDs). PDC is defined as the total number of days 
with possession of medication in a period of time; it avoids double counting when refills 
overlap with each other or oversupply of medications exists, but ignores the situations in 
which patients may refill their prescriptions before finishing the drug in hand and stockpile 
them for future use.e 
For each of the 4 drug therapies considered, patients were subdivided a priori into 2 
categories according to PDC: adherence (PDC ≥75%) and nonadherence (<75%).12,13 
Adherence to polytherapy was investigated dividing patients into 5 categories: no evidence-
based drug therapy (<%75 PDC of any of the drugs), and therapy with 1, 2, 3, or 4 evidence-
based drugs. 
2.4 Potential confounders 
We considered a number of potential confounders, measured before and at the index episode, 
known to be associated with mortality after AMI, and which might also influence the choice 
of secondary prevention medications. Specifically, we considered: index episode length of 
stay, ST-segment elevation (non-ST segment elevation [codes 410.71] vs. ST segment 
elevation [all remaining 410.x1 codes])f and revascularization procedures during the index 
episode (percutaneous coronary intervention [PCI] or bypass), as proxies of severity and 
intensity of care; 26 comorbidities retrieved from HDRs for both index episode and 2 years 
                                                 
e We used PDC because physicians usually prescribe a new active ingredient when the post-AMI 
patient has still in hand a drug belonging to the same 4th level ATC code. We are aware that this 
choice can lead to an underestimation of adherence.  
f The choice of combining ST segment elevation cases and AMIs of unspecified site was based on a 
preliminary Cox regression analysis. 
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before (Table S3 in the Appendix),g and use of specific drugs during the last 12 months prior 
to the index admission (defined as at least 3 filled prescriptions) (Table S4 in the Appendix). 
Comorbidities and previous drug treatments were investigated because the presence of 
certain conditions might increase the probability of receiving specific drug therapy, as they 
themselves require treatment with some of the ATC groups under study independently of 
AMI (e.g., statins for diabetic patients), and the presence of others might reduce drug 
prescription of specific ATC groups because of adverse effects and/or contraindications 
(e.g., β-blockers for patients with chronic obstructive pulmonary disease). Lastly, we 
considered the area-based index of socioeconomic position (SEP) based on 2001 Census 
block data (5 levels of SEP: high, medium-high, medium, medium-low, and low),h because 
some studies have demonstrated that it is associated with overall mortality and medication 
adherence.15,16 
2.5 Statistical analysis 
We analyzed the association between medication adherence and mortality using conditional 
logistic regression, which is appropriate for a time matched nested case-control design.17 In 
addition to age and sex on which the logistic regression was conditioned, we considered for 
inclusion in the models the confounders described above. Specifically, we adopted a 
bootstrap backward procedurei to determine which factors were significantly associated with 
the outcome.18 Using this approach, 200 replicated bootstrap samplesj were selected from the 
original cohort. A backward procedure was applied to each replicated sample with a 
                                                 
g Some conditions (diabetes, disorders of lipoid metabolism, hypertension, COPD) were not 
considered at the index episode, because they are not likely to be reported for very severe patients. 
h SEP index considers various socioeconomic parameters (occupation, education, housing tenure and 
family composition). It is a composite indicator derived from factor analysis, and the 5-level 
classification is based on a quintile split. 
i Bootstrap resampling allows including in the model only significant predictors which are not 
sensitive to a small change in the data. 
j A bootstrap sample is a sample of the same size as the original dataset chosen with replacement. A 
given subject in the original cohort may occur multiple times, only once, or not at all in a specific 
bootstrap sample. Bootstrap methods assess the stability of models and are useful for determining the 
strength of the evidence that a given variable truly is an independent predictor of the outcome. 
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significance level of removal =5%, and only risk factors selected in at least 50% of the 
replicates were included as confounders in the conditional logistic regression models. The 
variables included in the final models are reported in table footnotes. 
In the primary analysis, we compared patients adherent to 1, 2, 3 and 4 evidence-based 
medications with patients with no EB therapy (PDC <75% of any of the drugs). In secondary 
analysis, we investigated the role of each medication group under study (ACEIs/ARBs, β-
blocker, antiplatelet drugs, and statins) in reducing mortality. In all these analyses, we 
examined the role of patient’s age as an effect modifier by including interaction terms 
between age and drug adherence. 
2.5.1 Sensitivity analyses 
We carried out some sensitivity analyses to evaluate the robustness of the results. First, all 
analyses were replicated by restricting the study population to subjects who had not been 
hospitalized for AMI, other forms of ischemic heart disease, PCI, bypass, or surgery of the 
heart and great vessels in the 2 years before index admission (Table S3 in the Appendix). 
Second, we lowered the cutpoint for adherence from 75% to 60%. Lastly, the potential effect 
modification of time since index date was investigated: the observation period was 
subdivided into tertiles and an exposure by tertile interaction was included in the conditional 
logistic regression model. 
All analyses were carried out using Stata software, version 13 (StataCorp. 2013. Stata 
Statistical Software: Release 13. College Station, TX: StataCorp LP). 
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3 RESULTS 
Of the 5932 patients discharged after AMI, 4861 (81.9%) were enrolled in the study 
population (Figure 1). Patients’ characteristics overall and by age group (<80 vs. ≥80 years) 
are presented in Table 1. Mean age was 72 years, 62.5% were men, and the median follow-
up was 2.8 years. Forty-three percent of patients had an ST elevation AMI, 58.6% underwent 
PCI and 2.4% had bypass surgery. Some comorbid conditions were highly prevalent: 18.4% 
of patients had been previously diagnosed with hypertensive diseases, 12.3% had chronic 
nephropathies, 9.0% had diabetes, 8.8% had previous AMI, and 14.4% other forms of 
ischemic heart disease. More than two-thirds of patients (68.3%) had used antihypertensive 
drugs before the index AMI, while 7.7% had used drugs for obstructive airway diseases. 
When stratified by age group, we observed higher prevalence of prior drug therapies and 
comorbid conditions in very old subjects, while younger patients underwent more often PCI 
and bypass surgery (Table 1). 
Figure 1. Patients’ flow diagram 
 
 
 
 
 
 
 
 
 
 
Patients discharged after AMI between January 
1, 2008 and June 30, 2011 
(n =5932) 
Patients included in the study 
(n =4861) 
Patients excluded from study: 
1) Length of hospital stay >35 days (n =289) 
2) Age <37 years (n =24) 
Patients excluded from study: 
3) Death within 30 days of discharge (n =722) 
4) More than half of individual follow-up in 
hospital (n =56) 
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Table 1. Characteristics of post-AMI patients, overall and by age group 
Characteristics 
Age <80 years 
(n =3254) 
Age ≥80 years 
(n =1607) 
All patients 
(n =4861) P value 
n % n % n % 
        
Male 2347 72.1 692 43.1 3039 62.5 <0.001 
Socioeconomic position       0.21 
High 651 20.0 313 19.5 964 19.8  
Medium-high 519 16.0 257 16.0 776 16.0  
Medium 548 16.8 247 15.4 795 16.4  
Medium-low 579 17.8 295 18.4 874 18.0  
Low 711 21.9 393 24.5 1104 22.7  
Unknown 246 7.6 102 6.4 348 7.2  
ST segment elevation AMI 1552 47.7 537 33.4 2089 43.0 <0.001 
Bypass surgery 97 3.0 18 1.1 115 2.4 <0.001 
PCI 2240 68.8 608 37.8 2848 58.6 <0.001 
Length of hospital stay       <0.001 
<6 days 1384 43.2 280 17.7 1664 34.7  
6–9 days 1114 34.8 575 36.3 1689 35.3  
>9 days 707 22.1 731 46.1 1438 30.0  
Prior use of drugs        
Antidiabetic drugs 600 18.4 304 18.9 904 18.6 0.69 
Drugs for cardiac therapy 376 11.6 510 31.7 886 18.2 <0.001 
Drugs for obstructive airway 
diseases 219 6.7 153 9.5 372 7.7 <0.01 
Antihypertensive drugs 1969 60.5 1350 84.0 3319 68.3 <0.001 
Statins 736 22.6 382 23.8 1118 23.0 0.67 
Antiplatelet drugs 1120 34.4 883 55.0 2003 41.2 <0.001 
Comorbidities        
Malignant tumors 209 6.4 138 8.6 437 7.1 <0.01 
Diabetes 276 8.5 162 10.1 438 9.0 0.07 
Disorders of lipoid 
metabolism 215 6.6 87 5.4 302 6.2 0.11 
Obesity 112 3.4 12 0.8 124 2.6 <0.001 
Hematologic diseases 125 3.8 218 13.6 343 7.1 <0.001 
Hypertensive diseases 490 15.1 402 25.0 892 18.4 <0.001 
Old AMI 238 7.3 189 11.8 427 8.8 <0.001 
Other forms of ischemic heart 
disease 388 11.9 312 19.4 700 14.4 <0.001 
Ill-defined descriptions and 
complications of heart disease 19 0.6 11 0.7 30 0.6 0.70 
Rheumatic heart disease 23 0.7 49 3.1 72 1.5 <0.001 
Cardiomyopathies 86 2.6 56 3.5 142 2.9 0.10 
Acute endocarditis and 
myocarditis 2 0.1 1 0.1 3 0.1 >0.99 
Other cardiac diseases 64 2.0 56 3.5 120 2.5 <0.01 
Conduction disorders and 
cardiac dysrhythmias 125 3.8 181 11.3 306 6.3 <0.001 
Cerebrovascular diseases 176 5.4 235 14.6 411 8.5 <0.001 
Vascular diseases 209 6.4 152 9.5 361 7.4 <0.001 
COPD 168 5.2 148 6.2 316 6.5 <0.001 
Chronic nephropathies 255 7.8 345 21.5 600 12.3 <0.001 
Chronic diseases of liver, 
pancreas and intestine 41 1.3 19 1.2 60 1.2 0.89 
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Old bypass 80 2.5 64 4.0 144 3.0 <0.01 
Old PCI 227 7.0 100 6.2 327 6.7 0.32 
Cerebrovascular 
revascularization 14 0.4 12 0.8 26 0.5 0.21 
Other surgery of the heart 27 0.8 7 0.4 34 0.7 0.14 
Other surgery of great vessels 86 2.6 37 2.3 123 2.5 0.48 
Heart failure 117 3.6 183 11.4 300 6.2 <0.001 
Cardiac catheterization 6 0.2 3 0.2 9 0.2 >0.99 
        
Note: To analyze differences in characteristics across age groups we used χ² test and Fisher’s exact test, where appropriate. 
Abbreviations: AMI, acute myocardial infarction; PCI, percutaneous coronary intervention; COPD, chronic obstructive 
pulmonary disease. 
Table 2. Medication adherence (PDC ≥75%) overall and by age group (<80 vs. ≥ 80 years) 
during the observation follow-up period 
ACEIs/
ARBs β-blockers 
Antiplatelet 
drugs Statins 
Age <80 yrs Age ≥80 yrs All patients 
n % n % N % 
          
Nonadherence to any of the EB drugs 463 14.2 496 30.9 959 19.7 
          
Adherence to 1 EB drug 664 20.4 456 28.4 1120 23.0 
    285 42.9 202 44.3 487 43.5 
    24 3.6 15 3.3 39 3.5 
    264 39.8 223 48.9 487 43.5 
    91 13.7 16 3.5 107 9.6 
          
Adherence to 2 EB drugs 939 28.9 422 26.3 1361 28.0 
    95 10.1 24 5.7 119 8.7 
    422 44.9 277 65.6 699 51.4 
    162 17.3 39 9.2 201 14.8 
    40 4.3 23 5.5 63 4.6 
    8 0.9 4 0.9 12 0.9 
    212 22.6 55 13.0 267 19.6 
          
Adherence to 3 EB drugs 876 26.9 199 12.4 1075 22.1 
    186 21.2 49 24.6 235 21.9 
    59 6.7 10 5.0 69 6.4 
    570 65.1 125 62.8 695 64.7 
    61 7.0 15 7.5 76 7.1 
          
Adherence to 4 EB drugs 312 9.6 34 2.1 346 7.1 
          
Abbreviations: ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; EB, evidence-based. 
Table 2 shows patients’ adherence (as determined by the PDC) to 1, 2, 3, 4 or no evidence-
based (EB) drug therapies during the entire observation follow-up period: 19.7% of patients 
used no EB drug, 23.0% used 1 drug, 28.0% used 2 drugs, 22.1% used 3 drugs, and 7.1% 
used all of the 4 EB drug therapies. The highest adherence was found for ACEIs/ARBs 
(58.7%) and antiplatelet agents (59.0%), and the lowest for β-blockers (19.6%) and statins 
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(36.4%). The most common polytherapies were ACEIs/ARBs plus antiplatelet drugs 
(14.4%), and ACEIs/ARBs plus antiplatelet drugs plus statins (14.3%). The proportion of 
adherence to single and combination therapies was significantly lower among patients aged 
80 years or more, compared with those aged <80 years (P <0.001). Figure 2 illustrates 
changes in adherence to EB drugs in the 5-year observation period after AMI. The 
proportion of patients using a single medication (1 EB drug-group) within the first 6 months 
of discharge was ≈21% and remained stable over the entire observation period; on the 
contrary, the proportion of patients treated with 4 EB drugs fell from 12.5% to 4.1%. 
Figure 2. Changes in medication adherence over the 5-year observation period 
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3.1 Mortality 
Among the 4861 study patients, 1116 deaths occurred by natural causes (23.0%) during 
follow-up, yielding an overall incidence rate of 8.2/100 person-years. Cardiovascular causesk 
                                                 
k ICD-9-CM codes 390–459. 
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accounted for more than half of all natural causes (n =633), and only 35 deaths by external 
causes were observed. 
Table 3 shows the demographic and clinical characteristics of the cases (i.e., deaths by 
natural causes) and matched controls. As expected, cases were more likely to have malignant 
tumors, diabetes, chronic nephropathies, previous AMI and other cardiovascular diseases. 
Furthermore, cases differed from controls in terms of previous use of drug therapies (except 
statins), and PCIs were less common among cases than controls. The 2 groups did not differ 
significantly with respect to SEP. 
Table 3. Characteristics of cases and matched controls. 
Characteristics Cases (n =1116) Controls (n =8921) P value 
n % n % 
      
Socioeconomic position     0.54 
High 217 19.4 1774 19.9  
Medium-high 174 15.6 1449 16.2  
Medium 157 14.1 1384 15.5  
Medium-low 222 19.9 1642 18.4  
Low 276 24.7 2074 23.3  
Unknown 70 6.3 598 6.7  
ST segment elevation AMI 365 32.7 3341 37.5 <0.01 
Bypass surgery 11 1.0 156 1.8 0.06 
PCI 367 32.9 4342 48.7 <0.001 
Length of hospital stay     <0.001 
<6 days 173 15.7 2237 25.5  
6–9 days 371 33.8 3236 36.8  
>9 days 555 50.5 3311 37.7  
Prior use of drugs      
Antidiabetic drugs 283 25.4 1572 17.6 <0.001 
Drugs for cardiac therapy 387 34.7 2455 27.5 <0.001 
Drugs for obstructive airway diseases 137 12.3 823 9.2 <0.01 
Antihypertensive drugs 924 82.8 7114 79.7 0.02 
Statins 282 25.3 2042 22.9 0.67 
Antiplatelet drugs 609 54.6 4554 51.1 0.03 
Comorbidities      
Malignant tumors 157 14.1 684 7.7 <0.001 
Diabetes 195 17.5 763 8.6 <0.001 
Disorders of lipoid metabolism 78 7.0 528 5.9 0.16 
Obesity 17 1.5 140 1.6 >0.90 
Hematologic diseases 191 17.1 817 9.2 <0.001 
Hypertensive diseases 353 31.6 1987 22.3 <0.001 
Old AMI 187 16.8 885 9.9 <0.001 
Other forms of ischemic heart disease 285 25.5 1493 16.7 <0.001 
Ill-defined descriptions and 
complications of heart disease 12 0.9 79 1.1 0.50 
Rheumatic heart disease 36 3.2 223 2.5 0.15 
20 
 
Cardiomyopathies 51 4.6 224 2.5 0.10 
Acute endocarditis and myocarditis 2 0.2 4 0.04 0.14 
Other cardiac diseases 40 3.6 269 3.0 0.31 
Conduction disorders and cardiac 
dysrhythmias 159 14.3 742 8.3 <0.001 
Cerebrovascular diseases 180 16.1 977 11.0 <0.001 
Vascular diseases 150 13.4 735 8.2 <0.001 
COPD 156 14.0 703 7.9 <0.001 
Chronic nephropathies 302 27.1 1442 16.2 <0.001 
Chronic diseases of liver, pancreas and 
intestine 22 2.0 88 1.0 <0.01 
Old bypass 64 5.7 288 3.2 <0.001 
Old PCI 94 8.4 640 7.2 0.13 
Cerebrovascular revascularization 4 0.4 61 0.7 0.24 
Other surgery of the heart 14 1.3 49 0.6 <0.01 
Other surgery of great vessels 51 4.6 195 2.2 <0.001 
Heart failure 181 16.2 697 7.8 <0.001 
Cardiac catheterization 4 0.4 15 0.2 0.15 
      
Note: To analyze differences in characteristics across age groups we used χ² test and Fisher’s exact test, where appropriate. We 
do not report age, sex and duration of follow-up (i.e., matching variables). 
3.2 Effect of medication adherence on mortality 
Table 4 shows the results of the primary analysis. The unadjusted relationship between 
medication exposure and mortality exhibited a dose-response gradient; that is, compared 
with no EB drug-group, rate ratios of death linearly decreased as the number of EB drugs 
taken increased. After adjusting for significant baseline characteristics, results did not change 
appreciably: compared with patients with no EB drug therapy after AMI, the risk of 
mortality was 29% lower among those with 1 EB drug and 87% lower among those treated 
with all EB drugs. 
Table 4. Crude and adjusted association of medication adherence (PDC ≥75%) with 
mortality estimated by conditional logistic regression model. 
Drug 
exposure 
Crude 
rate ratio 95% CI P value 
Adjusted* 
rate ratio 95% CI P value 
       
No EB drug 1.00  <0.001† 1.00  <0.001† 
1 EB drug 0.66 0.56–0.78 <0.001 0.71 0.60–0.84 <0.001 
2 EB drugs 0.39 0.32–0.46 <0.001 0.46 0.38–0.55 <0.001 
3 EB drugs 0.24 0.19–0.30 <0.001 0.32 0.25–0.41 <0.001 
4 EB drugs 0.08 0.05–0.13 <0.001 0.13 0.08–0.21 <0.001 
       
*Adjusted for significant covariates, including age, PCI and bypass at index episode, length of index episode, previous use of 
antidiabetic drugs, malignant tumors, diabetes, hematologic diseases, old AMI, conduction disorders and cardiac dysrhythmias, 
vascular diseases, chronic nephropathies, and old bypass. 
†Test for linear trend across drug exposure groups. 
Abbreviations: CI, confidence interval. 
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As shown in Figure 3, mortality benefits associated with adherence to single and 
combination therapies were significant for both patients aged ≥80 years and those aged <80 
years, although the effect of single and double therapies (1 and 2 EB drug groups) was more 
evident among patients of <80 years of age. However, no significant effect modification by 
age was found. 
Figure 3. Adjusted rate ratios of death (with 95% CIs) as a function of medication adherence 
by age group (<80 vs. ≥ 80 years) 
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Note: No EB drug is the reference group. Rate ratios of death for <80-year group were adjusted for PCI and bypass at index 
episode, length of index episode, previous use of drugs for obstructive airway diseases, malignant tumors, diabetes, disorders of 
lipoid metabolism, COPD, and chronic nephropathies. Rate ratios of death for ≥80-year group were adjusted for age, PCI at 
index episode, length of index episode, previous use of antidiabetic drugs, malignant tumors, hematologic diseases, old AMI, 
conduction disorders and cardiac dysrhythmias, chronic nephropathies, chronic diseases of liver, pancreas and intestine, and old 
bypass surgery. 
In a secondary multivariate analysis, we investigated the role of each medication group 
under study (ACEIs/ARBs, β-blockers, antiplatelet drugs and statins) in reducing mortality. 
We found a significant overall association between the four medication groups and mortality, 
although the magnitude of this association was higher for ACEIs/ARBs (adj. rate ratio =0.60; 
95% CI =0.52–0.69; P <0.001) and statins (adj. rate ratio =0.60; 95% CI =0.50–0.72; P 
<0.001), and lower for β-blockers (adj. rate ratio =0.75; 95% CI =0.61–0.92; P <0.01) and 
antiplatelet drugs (adj. rate ratio =0.73; 95% CI =0.63–0.84; P <0.001). As expected, drugs 
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were more effective in reducing mortality when administered as combination therapies: 
Table 5 provides the rate ratios of death for the single and combination therapies most 
commonly observed among cases and matched controls (n >900). 
Table 5. Adjusted association of adherence to single and combination therapies (PDC ≥75%) 
with mortality estimated by conditional logistic regression model 
Drug 
exposure 
Adjusted* 
rate ratio 95% CI P value 
    
No EB drug 1.00   
ACEIs/ARBs only 0.61 0.48–0.77 <0.001 
Antiplatelet drugs only 0.80 0.63–0.96 0.02 
ACEIs/ARBs plus antiplatelet drugs 0.43 0.35–0.54 <0.001 
ACEIs/ARBs plus antiplatelet drugs plus statins 0.27 0.20–0.36 <0.001 
    
*Adjusted for significant covariates, including age, PCI and bypass at index episode, length of index episode, previous use of 
antidiabetic drugs, malignant tumors, diabetes, hematologic diseases, old AMI, conduction disorders and cardiac dysrhythmias, 
vascular diseases, chronic nephropathies, and old bypass. 
Note: We present rate ratios only for single and combination therapies with adequate sample size (n >900). 
Lastly, because of an interaction term (P =0.01) between antiplatelet drug exposure and 
patient’s age, an age-stratified analysis was carried out. In older age the overall effect of 
antiplatelet therapy on mortality was weaker (<80-year-old: adj. rate ratio = 0.60, 95% CI 
=0.46–0.77, P <0.001; ≥80-year-old: adj. rate ratio = 0.80, 95% CI =0.67–0.95, P =0.01) 
and, as illustrated in Figure 4, single use of antiplatelet drugs was associated with a lower 
mortality for <80-year patients (adj. rate ratio =0.61; 95% CI =0.40–0.91; P =0.02), but not 
for ≥80-year patients (adj. rate ratio =0.84; 95% CI =0.66–1.08; P =0.18). 
3.2.1 Sensitivity analyses 
To support the external validity of this study, we restricted the analyses to the 3817 incident 
cases of AMI, more similar to the “standard population” for whom treatment guidelines are 
tailored. As shown in Table S5 in the Appendix, results did not change appreciably: 
polytherapies were highly effective in reducing mortality, and a dose-response relationship 
was found between medication exposure and mortality. ACEIs/ARBs, antiplatelet drugs and 
statins proved to be effective in reducing mortality, whereas adherence to β-blockers did not 
achieve statistical significance because of the limited sample size (Table S6 in the 
Appendix). 
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Secondly, we lowered the PDC cutoff from 75% to 60% because prescribed daily doses 
(PDDs) for secondary prevention after AMI are generally lower than DDDs, possibly leading 
to misclassification bias. As shown in Table S7 and Table S8 in the Appendix, lowering the 
cutoff led to results consistent with those of the of primary and secondary analyses, although 
the adjusted relationship between reduced mortality and single medication therapy was no 
more statistically significant (Table S7). 
Figure 4. Adjusted rate ratios of death (with 95% CIs) as a function of adherence to 
antiplatelet medication by age group (<80 vs. ≥80 years) 
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Note: Rate ratio with red CI is not significantly different from 1 (α =5%). Rate ratios of death for <80-year group were adjusted 
for PCI and bypass at index episode, length of index episode, previous use of antiplatelet drugs, malignant tumors, diabetes, 
disorders of lipoid metabolism, COPD, and chronic nephropathies. Rates ratios of death for ≥80-year group were adjusted for 
age, PCI and bypass at index episode, length of index episode, previous use of antidiabetic drugs, hematologic diseases, old 
AMI, conduction disorders and cardiac dysrhythmias, vascular diseases, chronic diseases of liver, pancreas and intestine, and 
old bypass. 
After stratification by tertile of observation period (short-term: 1–8 months; medium-term: 
9–23 months; long-term: 24–60 months), the protective effect of polytherapy on mortality 
was confirmed, although it was more evident in the short-term period (Figure 5). On the 
contrary, we found a significant interaction between use of single therapies and time since 
index date (P =0.03); specifically, single therapy proved to be associated with short- and 
medium-term mortality, but not with long-term mortality (Figure 5). 
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Figure 5. Adjusted rate ratios of death (with 95% CIs) in short-, medium- and long-term 
observation period, as a function of medication adherence 
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Note: cut-off points were based on a tertile split. Rate ratio with red CI is not significantly different from 1 (α =5%). Rate ratios 
were adjusted for age, PCI and bypass at index episode, length of index episode, previous use of antidiabetic drugs, malignant 
tumors, diabetes, hematologic diseases, old AMI, conduction disorders and cardiac dysrhythmias, vascular diseases, chronic 
nephropathies, and old bypass. 
Abbreviations: FUP, follow-up. 
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4 DISCUSSION 
In this population-based study, we found that EB pharmacotherapy is effective in reducing 
mortality following AMI. Specifically, we observed a dose-type response gradient of 
mortality reduction with increasing number of EB drugs taken. Other observational studies 
of the impact of combination therapies on post-AMI long-term mortality had similar 
results,10-12,19 but did not investigate whether the magnitude of this relationship differed as a 
function of patients’ age. To this aim, we stratified analyses by age group and found that 
mortality benefits associated with EB polytherapies were significant for both patients aged 
≥80 years and those aged <80 years, even after 2 years of follow-up. This result suggests that 
the beneficial effect of combined use of the 4 EB drug therapies—as recommended by 
guidelines1,20—is evident also in nontrial older populations. However, prior studies have 
shown that medication nonadherence among older people is common,4,9,21 and our findings 
further support that very few octogenarians and older patients were adherent to the 4 EB 
drug therapies (2.1%). These data imply that quality improvement efforts should be made to 
include medication adherence as a key component of secondary prevention care in addition 
to prescription of indicated medications.4 These efforts include taking into consideration 
other medications the patient must take, scheduling when doses are to be taken, providing 
individualized medication education, helping the patient select a reminder cue, and ensuring 
regular follow-up with clinical pharmacists.22,23 
Meta-analyses of randomized clinical trials of secondary prevention found that β-blocker use 
was associated with a 23% relative risk reduction in all-cause mortality, while the magnitude 
of relative mortality risk reductions ascribable to ACEIs/ARBs and statins was mildly lower 
(13% and 21%, respectively).1 On the contrary, our study demonstrated modest superiority 
of ACEIs/ARBs and statins over β-blockers. Indeed, the evidence of benefits associated with 
β-blocker use is mostly from trials predating the advent of modern reperfusion therapy,24 and 
some authors have argued that the incremental survival benefits associated with β-blockers 
in the era of early revascularization might be less pronounced than those observed for other 
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EB medications, especially among lower risk AMI populations with preserved left 
ventricular function.25 
An interesting finding of the present study is the differential effect of antiplatelet therapy on 
mortality by age group. Specifically, we found a 40% risk reduction in mortality among 
elderly and adults, and a 20% risk reduction among octogenarians and older patients. We 
know from the Global Registry of Acute Coronary Events (GRACE) and the Thrombolysis 
in Myocardial Infarction (TIMI) Study Group that older patients are at higher risk of 
bleeding episodes.26,27 Not only does bleeding result in an immediate threat, but it is also 
associated with increased coronary artery disease mortality and reinfarction, both in the short 
and the long term.28 Thus, it is reasonable to infer that the risk-benefit ratio associated with 
antiplatelet therapy is less favorable for very old subjects than for elderly and adults. Our 
finding suggests that the management of secondary prevention after AMI in older patients 
should balance the risk of recurrent acute coronary syndrome episodes and the risk of 
bleeding. Such a strategy includes assessing the individual risk of bleeding, selecting the 
antiplatelet agent that is best for the patient, using the correct dose of medications, 
recognizing the early signs of bleeding and using gastroprotective agents to minimize upper 
gastrointestinal bleeding. 28 
4.1 Strengths and limitations 
This study has some noteworthy strengths. First, both exposure and covariate definitions 
were time dependent because we used a risk set sampling that attributes the same length of 
observation to case and matched controls and ensures an equal time window to measure 
exposure; in this way we prevented time-related bias, which may produce illusory results in 
favor of the treatments under study.29,30 Second, drug exposure was prospectively collected, 
removing the possibility of recall bias.31 Third, we did several sensitivity analyses which, 
overall, produced results consistent with those of the primary and secondary analyses. 
This study has also several limitations. First, we were unable to track relevant clinical 
information (e.g., body mass index and severity of AMI). Although our analyses were 
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adjusted for many factors including SEP, comorbid conditions, and concomitant and 
preexisting use of EB therapies, it is possible that the lack of more detailed clinical data 
leaves room for residual confounding. In sensitivity analysis, we tried to address this 
limitation by restricting the study population to cases with no history of AMI and coronary 
disease—that is, a subgroup of “clinically homogeneous” patients. Of note, results did not 
change appreciably and the trend of mortality reduction with increasing number of EB drugs 
was still evident. 
Second, we had no information on lifestyle behaviors (e.g., smoking, diet, and physical 
activity); nonetheless, available evidence has shown that adherence-related mortality benefits 
associated with evidence-based medication are mediated by drug effects more than by 
generic health adherer behavioral attributes.32 
Third, we used pharmacy data on filled prescriptions to estimate adherence, but had no 
information on actual medication consumption. Furthermore, DDDs may have caused an 
underestimation of adherence, because they are generally higher than PDDs for secondary 
prevention after AMI. However, when we lowered the cutoff of adherence from 75% to 60% 
results remained stable. 
Lastly, our study is based on post-AMI patients resident in the Local Health Authority of 
Bologna, the capital of Emilia-Romagna region in Italy. Nevertheless, our study is 
comprehensive, consisting of all patients in one of the largest Local Health Authorities of 
Italy, and there is no reason to deem that our findings would not be generalizable to other 
jurisdictions that have similar drug reimbursement policies to that of Italy. 
4.2 Conclusions 
This population-based study indicates that the beneficial effect of EB polytherapy on long-
term mortality following AMI is evident also in nontrial older populations. Given that 
adherence to combination therapies has been shown to be largely suboptimal, the 
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implementation of strategies and initiatives to increase the use of post-AMI secondary 
preventive medications in old patients is crucial. 
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APPENDIX 
Table S1. ICD-9-CM codes for identification of AMI cases: primary diagnosis of AMI 
(410.x1) or secondary diagnosis of AMI (410.x1) associated with one of the following 
conditions as primary diagnosis 
ICD-9-CM code Condition 
  
411 Other acute and sub-acute forms of ischemic heart disease 
413 Angina pectoris 
414 Other forms of chronic ischemic heart disease 
423.0 Hemopericardium 
426 Conduction disorders 
427 Cardiac dysrhythmias 
428 Heart failure 
429.5 Rupture of chordae tendineae 
429.6 Rupture of papillary muscle 
429.71 Acquired cardiac septal defect 
429.79 Certain sequelae of myocardial infarction not elsewhere classified other 
429.81 Other disorders of papillary muscle 
518.4 Acute edema of lung unspecified 
518.81 Acute respiratory failure 
780.01 Coma 
780.2 Syncope and collapse 
785.51 Cardiogenic shock 
799.1 Respiratory arrest 
997.02 Iatrogenic cerebrovascular infarction or hemorrhage 
998.2 Accidental puncture or laceration during a procedure 
  
Abbreviations: ICD-9-CM, International Classification of Diseases (Clinical Modification, 9th revision); AMI, acute myocardial 
infarction. 
 
Table S2. Therapeutic indications, side effects and main warnings for post-AMI secondary 
prevention medications 
 
ACEIs 
Therapeutic indications: Essential hypertension, acute coronary syndrome with ST segment 
elevation, chronic heart failure, diabetic nephropathy. 
Side effects: The most common side effect is dry cough due to increased levels of bradykinin. 
Main warnings: In some patients, administration of ACEIs can cause fast arterial pressure-
relieving, especially when they also take diuretics. Do not prescribe to patients allergic to 
ACEIs; to be avoided during pregnancy. 
 
ARBs 
Therapeutic indications: Hypertension, heart failure, diabetic nephropathy. 
Side effects: No important side effect is related to ARBs use; sometimes hypotension can occur. 
Main warnings: To be avoided during pregnancy and breastfeeding; pay attention if the patient 
has a diagnosis of renal artery stenosis.  
Note: Weak evidence of carcinogenic effects and low efficacy in comparison with ACEIs put this 
class as a second choice in recent local recommendations. 
 
β-blockers 
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Therapeutic indications: Angina pectoris, heart attack, arrhythmia, chronic heart failure, 
hypertension. 
Side effects: Bronchoconstriction, bradycardia, hypoglycemia, fatigue, cold hands and feet, 
sleep disturbance and nightmares. 
Main warnings: To be avoided if the patient has a history of asthma; pay attention to patients 
with a diagnosis of diabetes. 
 
Antiplatelet drugs 
Therapeutic indications: AMI, prevention of angina, myocardial infarction and claudicatio, 
after bypass implantation and angioplasty or stenting of coronary artery. 
Side effects: Aspirin can cause dyspepsia and peptic ulcer disease. When additional risk factors 
are present, gastroprotective therapy can be associated. 
Main warnings: If gastric disorders occur, give clopidogrel instead of aspirin. 
 
Statins 
Therapeutic indications: Secondary prevention of myocardial infarction and ictus, severe 
dyslipidemia. 
Side effects: Skeletal muscles disorders (myalgia, myositis, myopathy), increased levels of 
hepatic enzymes, insomnia, rashes. 
Main warnings: Pay attention if patients have a history of hepatic disease or abnormal use of 
alcohol. 
 
Abbreviations: ACEIs/ARBs, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers. 
 
Table S3. ICD-9-CM codes for identification of comorbid conditions 
Condition 
ICD-9-CM codes 
AMI episode Hospital admissions in the previous 2 years 
 
Malignant tumors 140.0–208.9, V10 140.0–208.9, V10
Diabetes 250.0–250.9
Disorders of lipoid metabolism 272
Obesity 278.0 278.0
Hematologic diseases 280–285, 288, 289 280–285, 288, 289
Hypertensive diseases 401–405
Old AMI 412 410, 412
Other forms of ischemic heart 
disease 411, 413, 414
Ill-defined descriptions and 
complications of heart disease 429
Rheumatic heart disease 393–398 391, 393–398
Cardiomyopathies 425 425
Acute endocarditis and 
myocarditis 421, 422
Other cardiac diseases 745, V15.1, V42.2, V43.2, V43.3, V45.0
745, V15.1, V42.2, V43.2, 
V43.3, V45.0
Conduction disorders and cardiac 
dysrhythmias 426, 427
Cerebrovascular diseases 433, 437, 438 430–432, 433, 434, 436, 437, 438
Vascular diseases 
440–448 (except 441.1, 
441.3, 441.5, 441.6, 444), 
557.1
440–448, 557
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COPD 491–492, 494, 496
Chronic nephropathies 582–583, 585–588 582–583, 585–588
Chronic diseases of liver, 
pancreas and intestine 
571–572, 577.1–577.9, 
555, 556
571–572, 577.1–577.9, 
555, 556
Old bypass surgery V45.81 V45.81, 36.1
Old PCI V45.82 V45.82, 36.0, 00.66
Cerebrovascular revascularization 00.61, 00.62, 38.01, 38.02 38.11, 38.12, 38.31, 38.32
Other surgery of the heart 35, 37.0, 37.1, 37.3, 37.4, 37.5, 37.6, 37.9
Other surgery of great vessels 
38–39.5 (except 38.01, 
38.02, 38.5, 38.11, 38.12, 
38.31, 38.32, 38.93)
Heart failure 428
Cardiac catheterization 38.93
 
Abbreviations: COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention. 
 
Table S4. Medication use over 12 months before AMI 
Medication ATC codes 
  
Antidiabetic drugs A10 
Drugs for cardiac therapy C01 
Drugs for obstructive airway diseases R03 
Antihypertensive drugs 
C02 (antihypertensive drugs), C03 (diuretics), C07 (β-
blockers), C08 (calcium channel blockers), C09 
(ACEIs/ARBs)  
Statins C10AA 
Antiplatelet drugs B01AC 
  
 
 
Table S5. Crude and adjusted association of medication adherence (PDC ≥75%) with 
mortality estimated by conditional logistic regression model (only incident cases of AMI) 
Drug 
exposure 
Crude 
rate ratio 95% CI P value 
Adjusted* 
rate ratio 95% CI P value 
       
No EB drug 1.00  <0.001† 1.00  <0.001† 
1 EB drug 0.66 0.54–0.81 <0.001 0.70 0.57–0.87 <0.01 
2 EB drugs 0.38 0.31–0.48 <0.001 0.45 0.36–0.56 <0.001 
3 EB drugs 0.24 0.18–0.31 <0.001 0.31 0.23–0.42 <0.001 
4 EB drugs 0.09 0.05–0.16 <0.001 0.13 0.07–0.24 <0.001 
       
*Adjusted for significant covariates, including age, ST segment elevation, PCI and bypass at index episode, length of index 
episode, previous use of antidiabetic drugs, malignant tumors, diabetes, chronic nephropathies, and heart failure. 
†Test for linear trend across drug exposure groups. 
Note: We excluded patients hospitalized for AMI, other cardiac disease, PCI, bypass or surgery of the heart and great vessels 
before index admission (n =1044). 
Abbreviations: CI, confidence interval. 
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Table S6. Adjusted association of medication adherence to the 4 medication groups (PDC 
≥75%) with mortality (only incident cases of AMI) 
Drug 
exposure 
Adjusted* 
rate ratio 95% CI P value 
    
ACEIs/ARBs    
Nonadherence 1.00   
Adherence 0.57 0.48–0.69 <0.001 
β-blockers    
Nonadherence 1.00   
Adherence 0.88 0.68–1.13 0.32 
Antiplatelet drugs    
Nonadherence 1.00   
Adherence 0.70 0.59–0.84 <0.001 
Statins    
Nonadherence 1.00   
Adherence 0.60 0.47–0.75 <0.001 
    
*Adjusted for significant covariates, including age, ST segment elevation, PCI and bypass at index episode, length of index 
episode, previous use of antidiabetic drugs, malignant tumors, diabetes, chronic nephropathies, and heart failure. 
Note: We excluded patients hospitalized for AMI, other cardiac disease, PCI, bypass or surgery of the heart and great vessels 
before index admission (n =1044). 
 
Table S7. Crude and adjusted association of medication adherence (PDC ≥60%) with 
mortality estimated by conditional logistic regression model 
Drug 
exposure 
Crude 
rate ratio 95% CI P value 
Adjusted* 
rate ratio 95% CI P value 
       
No EB drug 1.00  <0.001† 1.00  <0.001† 
1 EB drug 0.77 0.63–0.93 <0.01 0.85 0.70–1.04 0.13 
2 EB drugs 0.53 0.44–0.64 <0.001 0.61 0.50–0.74 <0.001 
3 EB drugs 0.25 0.20–0.30 <0.001 0.32 0.26–0.40 <0.001 
4 EB drugs 0.14 0.10–0.18 <0.001 0.21 0.15–0.28 <0.001 
       
*Adjusted for significant covariates, including age, PCI and bypass at index admission, length of index episode, previous use of 
antidiabetic drugs, malignant tumors, diabetes, hematologic diseases, old AMI, conduction disorders and cardiac dysrhythmias, 
vascular diseases, chronic nephropathies, and old bypass. 
†Test for linear trend across drug exposure groups. 
 
Table S8. Adjusted association of medication adherence to the 4 medication groups (PDC 
≥60%) with mortality (only incident cases of AMI) 
Drug 
exposure 
Adjusted* 
rate ratio 95% CI P value 
    
ACEIs/ARBs    
Nonadherence 1.00   
Adherence 0.57 0.50–0.66 <0.001 
β-blockers    
Nonadherence 1.00   
Adherence 0.65 0.55–0.77 <0.001 
Antiplatelet drugs    
Nonadherence 1.00   
Adherence 0.80 0.69–0.94 <0.01 
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Statins    
Nonadherence 1.00   
Adherence 0.69 0.58–0.81 <0.001 
    
*Adjusted for significant covariates, including age, PCI and bypass at index admission, length of index episode, previous use of 
antidiabetic drugs, malignant tumors, diabetes, hematologic diseases, old AMI, conduction disorders and cardiac dysrhythmias, 
vascular diseases, chronic nephropathies, and old bypass. 
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